Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$12.42 - $23.81 $167,111 - $320,363
-13,455 Reduced 27.13%
36,148 $449,000
Q4 2020

Feb 16, 2021

BUY
$10.55 - $18.69 $523,311 - $927,080
49,603 New
49,603 $888,000

Others Institutions Holding DCTH

About DELCATH SYSTEMS, INC.


  • Ticker DCTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 8,597,680
  • Market Cap $100M
  • Description
  • Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...
More about DCTH
Track This Portfolio

Track Alyeska Investment Group, L.P. Portfolio

Follow Alyeska Investment Group, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alyeska Investment Group, L.P. with notifications on news.